Literature DB >> 25732546

NICE guidance on axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment.

Nwamaka Umeweni1, Boglarka Mikudina2, Frances Sutcliffe2, Andrew Stevens2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25732546     DOI： 10.1016/S1470-2045(14)70484-X

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  2 in total

1.  Second-line treatment for metastatic clear cell renal cell cancer: experts' consensus algorithms.

Authors:  C Rothermundt; J von Rappard; T Eisen; B Escudier; V Grünwald; J Larkin; D McDermott; J Oldenburg; C Porta; B Rini; M Schmidinger; C N Sternberg; P M Putora
Journal:  World J Urol       Date:  2016-08-03       Impact factor: 4.226

2.  Real-world treatment sequencing and survival in previously treated advanced renal cell carcinoma patients receiving nivolumab monotherapy: a UK retrospective cohort study.

Authors:  T Waddell; K Fife; R Griffiths; A Sharma; P Dhokia; L Groves; M Hurst; C Tsang; D Sugrue; S McKenna; J Houghton; R Carroll
Journal:  BMC Cancer       Date:  2022-06-06       Impact factor: 4.638
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.